Studies of amino acids for inhibition of aldol condensation and dissolution of polymeric product of aldehyde in alkaline media

Theoretical Study of the Histidine-catalyzed Asymmetric Aldol Reaction of Acetone and Benzaldehyde

The mechanism of histidine-catalyzed asymmetrical aldol reaction of acetone with benzaldehyde was studied by using B3LYP method of density functional theory at the levels of 6-31G(d,p) and cc-pvdz basis sets. The calculation results showed that the reaction mechanism included four steps: (I) nucleophilic attack of histidine on acetone to form alcohol intermediate Inter-A through the transition state TS1 (considered a rate control step because the activation energy (49.95 kcal/mol) was relatively high); (II) dehydration of the alcohol intermediate to form the cis- or trans-enamine through the transition states TS3 and TS4 with the energy barriers of 36.12 and 38.15 kcal/mol; (III) electrophilic addition of cis-enamine or trans-enamine with benzaldehyde to form imine Inter-C or Inter-E through the transition states TS8, TS9, TS10, and TS11 (energy barriers 18.43, 22.34, 13.24, and 13.24 kcal/mol, respectively); (IV) after combination of the imine intermediate with water through the transition states TS12, TS13, TS14, and TS15 (energy barriers 22.79, 34.6, 28.2, 25.12 kcal/mol, respectively), removal of the histidine catalys to obtain the final S or R aldol product. Through analyzing the potential energy profile of reaction, we found that the histidine-catalyzed reaction of acetone with benzaldehyde was more energetically favorable to obtain the R-product (ee value >99%). Solvent effects computed with a polarizable continuum model (PCM) indicated that the DMSO and water can reduce the reaction energy barrier.

Functionalization of mesoporous organosilica nanocarrier for pH/glutathione dual-responsive drug delivery and imaging of cancer therapy process

A multifunctional drug nanocarrier is developed by incorporating acetaldehyde-modified-cystine (AMC) into mesoporous organosilica nanoparticles (MONs), shortly termed as MONs-AMC. The anticancer drug doxorubicin (DOX) links directly to MONs-AMC through electrostatic interaction between DOX and AMC to produce a conjugate, MONs-AMC-DOX, with a drug loading efficiency of 26.24 ± 1.35%, corresponding to a loading capacity of 0.26 ± 0.01mgmg^-1 for DOX. Schiff base AMC contains a -S-S- bond and two -C˭N- bonds which cleave in the presence of certain level of GSH and in an acidic medium, providing MONs-AMC-DOX the capability for triggering pH and glutathione (GSH) dual-responsive drug release. Further, the self-fluorescent nature of AMC offers the tracing capability without the need of fluorescent label, which facilitates real-time tracing of the drug delivery and cancer therapy process. With 10mmolL^-1 GSH and at pH 5.0, a drug release efficiency of 52.27 ± 2.84% is achieved. The intracellular drug release process is traced with confocal laser scanning microscope by monitoring the green fluorescence of MONs-AMC-DOX and red fluorescence of DOX with excitation at 408nm and 488nm, respectively. The drug loaded nanocarriers exhibit a time-dependent cellular uptake behavior, providing an enhanced therapeutic effect to A549 cancer cells.